Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer

This publication has 34 references indexed in Scilit:

• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
  The Lancet, 2010
• Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
  PLOS ONE, 2009
• Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines withMETAmplification
  Clinical Cancer Research, 2009
• Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells
  Molecular Cancer Therapeutics, 2008
• BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
  PLOS Medicine, 2007
• Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas
  PLOS Medicine, 2007
• A Novel Epidermal Growth Factor Receptor Inhibitor Promotes Apoptosis in Non–Small Cell Lung Cancer Cells Resistant to Erlotinib
  Cancer Research, 2007
• Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
  Nature, 2007
• Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling
  Clinical Cancer Research, 2006
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogene
  Science, 1987